Drugs

Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer

Thursday, September 17, 2020 - 9:00pm

POMEZIA, Italy, Sept. 17, 2020 /PRNewswire/ --Menarini Ricerche, the R&D division of the Menarini Group, today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611, a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor in development for the treatment of breast cancer.

Key Points: 
  • POMEZIA, Italy, Sept. 17, 2020 /PRNewswire/ --Menarini Ricerche, the R&D division of the Menarini Group, today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611, a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor in development for the treatment of breast cancer.
  • B-PRECISE-01 is an open-label, multicenter, phase Ib, dose escalation and expansion study conducted in patients withHER2-positive, PIK3CAmutated, advanced or metastatic breast cancer, which has progressed after at least two lines of anti-HER2-based therapy.
  • The primary objectives of the study were to determine the safety and the recommended Phase 2 dose (RP2D) of MEN1611 in combination with trastuzumab +/- fulvestrant.
  • Through the work of Menarini Silicon Biosystems, Menarini is also developing advanced technologies and products to study rare cells with single-cell precision.

'Know Your Potential' with Knosis - Cognizin® Citicoline Featured in New Nootropic + Energy Blend

Thursday, September 17, 2020 - 7:00pm

That's why Kyowa Hakko's Cognizin Citicoline ingredient is so critical to the efficacy and uniqueness of our product."

Key Points: 
  • That's why Kyowa Hakko's Cognizin Citicoline ingredient is so critical to the efficacy and uniqueness of our product."
  • Cognizin Citicoline is a patented, branded form of citicoline that is made by leading international health ingredient manufacturer, Kyowa Hakko, through a fermentation process.
  • Citicoline is a potent brain-health nutrient and nootropic that is especially vital to brain health and the formation of phospholipids.
  • A proprietary form of citicoline, Cognizin has been clinically studied to support mental energy, focus, attention, and recall.

Stability Cannabis Voted "Best Cannabis Retail Store" in Oklahoma

Thursday, September 17, 2020 - 6:02pm

OKLAHOMA CITY, Sept. 17, 2020 /PRNewswire/ --Stability Cannabis, one of Oklahoma's largest cultivators and distributors of medical marijuana, has been voted "Best Cannabis Retail Store" by readers of the Oklahoman for 2020.

Key Points: 
  • OKLAHOMA CITY, Sept. 17, 2020 /PRNewswire/ --Stability Cannabis, one of Oklahoma's largest cultivators and distributors of medical marijuana, has been voted "Best Cannabis Retail Store" by readers of the Oklahoman for 2020.
  • "Stability Cannabis is honored to be voted the best cannabis retail store in Oklahoma!We are especially proud of all our dispensary employees who create the most welcoming and supportive atmosphere for patients in the entire state," said chief executive officer Denver Kitch.
  • Stability opened the 4,000 square foot cannabis superstore in January 2020 and has served patients from 72 of Oklahoma's 77 counties.
  • Oklahoma Citybased Stability Cannabis operates one of the largest indoor cannabis cultivation, processing and retail operations in Oklahoma with a 90,000 sq.

CCSA to Lead Update of Canada’s Low-Risk Drinking Guidelines

Thursday, September 17, 2020 - 6:30pm

OTTAWA, Sept. 17, 2020 (GLOBE NEWSWIRE) -- The Canadian Centre on Substance Use and Addiction (CCSA) is leading a major collaborative initiative to update Canadas Low-Risk Alcohol Drinking Guidelines by March 2022.

Key Points: 
  • OTTAWA, Sept. 17, 2020 (GLOBE NEWSWIRE) -- The Canadian Centre on Substance Use and Addiction (CCSA) is leading a major collaborative initiative to update Canadas Low-Risk Alcohol Drinking Guidelines by March 2022.
  • Canadas first Low-Risk Alcohol Drinking Guidelines were developed in 2011 to support Canadians in making informed decisions about their alcohol consumption.
  • Rita Notarandrea, CCSAs CEO, said: CCSA is thrilled to lead the initiative to update Canadas Low-Risk Alcohol Drinking Guidelines by March 2022.
  • The current Low-Risk Alcohol Drinking Guidelines are a vital tool to support Canadians in assessing their alcohol consumption and in making informed decisions about drinking.

CBD Validator Announces Key Milestones of Growth and Expansion - New Enhanced Rating System and the Largest Independent Database of Rated CBD Oil Products

Thursday, September 17, 2020 - 4:00pm

One new feature to the rating system includes the designation of ISO 17025 accredited for a testing laboratory in the evaluation.

Key Points: 
  • One new feature to the rating system includes the designation of ISO 17025 accredited for a testing laboratory in the evaluation.
  • CBD Validator's new rating system for pricing is based on a tiered analysis of its database of over 2,000 CBD oil products.
  • Each product receives a CBD Validator Score based on how it meets key criteria outlined in the proprietary 50-point rating system .
  • CBD Validator is a completely independent resource, not sponsored by any manufacturer of CBD products, and does not accept advertising or receive sales commissions from any manufacturers or marketers of CBD products.

Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer

Thursday, September 17, 2020 - 4:00pm

POMEZIA, Italy, Sept. 17, 2020 /PRNewswire/ --Menarini Ricerche, the R&D division of the Menarini Group, today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611, a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor in development for the treatment of breast cancer.

Key Points: 
  • POMEZIA, Italy, Sept. 17, 2020 /PRNewswire/ --Menarini Ricerche, the R&D division of the Menarini Group, today announced the results of the dose escalation part of its B-PRECISE-01 clinical trial (NCT03767335) which is evaluating MEN1611, a potent and selective phosphatidylinositol 3-kinase (PI3K) inhibitor in development for the treatment of breast cancer.
  • B-PRECISE-01 is an open-label, multicenter, phase Ib, dose escalation and expansion study conducted in patients withHER2-positive, PIK3CAmutated, advanced or metastatic breast cancer, which has progressed after at least two lines of anti-HER2-based therapy.
  • The primary objectives of the study were to determine the safety and the recommended Phase 2 dose (RP2D) of MEN1611 in combination with trastuzumab +/- fulvestrant.
  • Through the work of Menarini Silicon Biosystems, Menarini is also developing advanced technologies and products to study rare cells with single-cell precision.

Compelling New Research Links Increased Omega-3 Intake to Improved Cardiovascular Outcomes

Thursday, September 17, 2020 - 3:30pm

Published in Mayo Clinic Proceedings , the meta-analysis is an in-depth review of 40 clinical trials.

Key Points: 
  • Published in Mayo Clinic Proceedings , the meta-analysis is an in-depth review of 40 clinical trials.
  • Cardiovascular benefits appear to increase with dosage.
  • This new paper encompasses more than triple the number of studies, which is the totality of the evidence to date.
  • "Because this paper included more studies andall dosages, the estimates for a dose-response are more precise and the conclusions stronger."

Kannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of Advisors

Thursday, September 17, 2020 - 2:00pm

We are pleased and excited to have him on board.

Key Points: 
  • We are pleased and excited to have him on board.
  • Honor developed to obtain record pipeline productivity in several companies are key to his business achievements.
  • Atopidine is Kannalifes novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing.
  • The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces August 2020 as the Best Revenue Month in Company History

Thursday, September 17, 2020 - 2:00pm

Since 2015, HempMeds Brasil has sold more than 80,000 units of cannabidiol (CBD) to Brazilian citizens, said Medical Marijuana, Inc. CEO Dr. Stuart Titus.

Key Points: 
  • Since 2015, HempMeds Brasil has sold more than 80,000 units of cannabidiol (CBD) to Brazilian citizens, said Medical Marijuana, Inc. CEO Dr. Stuart Titus.
  • Before becoming Co-CEO of HempMeds operations, Heinz served as Vice President of HempMeds Brasil.
  • She was also able to establish two HempMeds Brasil offices and create a network of Brazilian doctors and medical professionals.
  • To learn more about HempMeds Brasil, please visit them online at https://hempmedsbr.com/ or on Instagram at https://www.instagram.com/hempmedsbrasil/ .

Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb Company

Thursday, September 17, 2020 - 1:03pm

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID (lenalidomide) Capsules.

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID (lenalidomide) Capsules.
  • Dr. Reddys is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026.
  • Revlimid is a trademark of Celgene, a wholly owned subsidiary of Bristol Myers Squibb.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.